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Abstract Background Generics have the potential to
contain drug therapy costs; successful implementation of
generic substitution policy largely depends on consumers’
willingness to choose generics. Objective This study aims to
analyse the opinions, experiences and preferences of Polish
patients towards generic medicines. Setting The study was
performed in Poland. Method The survey was conducted in
June 2013 by means of face-to-face interviews. Respondents
were drawn from the general population according to a
population structure. The study covered a representative
sample of 1,000 Poles; the results can be generalized to apply
to the Polish population at large. Results Fifty-two percent of
respondents declared to be more often choosing generics,
twenty-three percent did not have any specific preferences,
and twenty-five percent were more willing to choose brand-
name medicines. Past experience with cheaper generic
medicines, secondary or lower education, low income and
residence in specific regions of Poland were all significantly
associated with an increased willingness to choose generics.
Respondents’ attitudes towards generics were mostly influ-
enced by the opinions of doctors and pharmacists. According
to respondents, attitudes towards generics among doctors,
pharmacists, family and friends, and in the mass media were
mostly positive. There was no relationship between the
preference of respondents for generics and factors such as
their age, life stage, gender, household size or urban/rural
locality. As a result of substituting a brand-name drug with
its generic equivalent, 72 % of respondents reported that
they had not noticed any difference in drug effectiveness;
21 % had experienced a reduced effectiveness of treatment
or increased side effects at least once; and 7 % claimed the
generic worked better. The majority of respondents who used
cheaper substitutes claimed that generics represented good
or very good quality. Conclusion The study demonstrates
that, when choosing medicines, Poles rely mainly on the
opinions of their doctors and pharmacists. Therefore, it is
recommended that: (1) the option of using generics be pro-
moted when writing prescriptions, and (2) the obligation on
pharmacists to inform customers of their option to purchase
generics be enforced.
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Impacts on practice
• Polish people generally prefer generic medicines over
original medicines because they find them equally
effective.
• A significant proportion of the Polish population have
never used a generic substitute for an original drug.
Therefore generic prescribing should be promoted, and
pharmacists should meet their obligation to inform
patients of cheaper medicines.
• Doctors and pharmacists were found to shape patients’
perception of generic medicines. Improved communi-
cation between patients and healthcare professionals
around generics is recommended.
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Introduction
In 2010, the market share of generics in Poland was estimated
at 40 % in value terms and 50 % in volume terms [1]. Drug
prices in Poland are some of the lowest in Europe. Nonethe-
less, nearly 30 % of Polish patients do not use the prescriptions
issued to them due to patient co-payment levels remaining
very high [2], and only 18 % of medicines eligible for reim-
bursement being fully exempt from patient co-payment.
Increasing market share of generic medicines is seen as a
remedy for the excessive financial strain caused by high drug
spending and still insufficient access to medicines among
some patient groups. Therefore, according to the Polish
Ministry of Health, ‘‘the national drug policy should strive to
rationalise pharmacotherapy expenditure to streamline
access to cheap generic medicines’’ [3]. The escalating costs
and affordability of medicines have become a burden for
both governments and patients worldwide. One of the main
methods of boosting the use of generics, and in the long term
also cutting drug therapy costs, is generic substitution (GS).
Generic substitution policies have been implemented across
the world to promote the use of low-priced generic medicines
[4–7]. Under the Polish legal framework, in the case of reim-
bursable medicines, pharmacists are committed to substituting
prescribed medicines for cheaper generic alternatives, unless
the patient or the prescribing doctor opposes such a substitution
[8]. Also, patients’ preferences have proved to be an obstacle in
promoting generic prescription. From the patient perspective,
the perceived quality of original medicines may be higher as
compared to that of generic medicines [9].
Aim of the study
The aims of this study were to evaluate consumers’ expe-
rience with generic medicines, find out whether consumers
would be willing to use generic medicines, and investigate
what are the factors influencing their choices. There was a
need to study how often GS was the cause of altered or
enhanced adverse effects in drug therapy. The perception
of generics among family and friends, doctors, pharma-
cists, and the mass-media has also received attention. To
the best of our knowledge, this is the first published
study—that can be generalized to the whole Polish popu-
lation—which explores factors determining patient choice
of the type of prescribed medicines.
Ethical approval
The Ethics Committee of the Medical University of War-




The study sample was a representative selection of 1,000
Poles from across Poland, offering the highest sample
representativeness. A representative sample of the target
population by definition allows researchers to draw valid
conclusions about the studied phenomenon in the popula-
tion at a predetermined significance level. In the present
study, the prediction error is 3.16 % at 95 % statistical
significance. This means, that the values determined in the
study do not differ from population-wide values by more
than 3.16 %.
The sample was randomly selected. Respondents were
drawn from the population according to a population
structure defined in the Electronic System of Population
Register (PESEL) kept by the Polish Ministry of Internal
Affairs. In accordance with art. 44 h, para. 2.2 of the Act
on Registration of the Population and Identity Cards [PL:
ustawa o ewidencji ludnos´ci i dowodach osobistych] dated
10 April 1974, the Ministry of the Interior made PESEL
(national identification) numbers available to the authors
for the purpose of conducting a public opinion poll. The
PESEL numbers were chosen at random by custom
designed software written by programmers at the Polish
Ministry of Internal Affairs.
First the sample was stratified by nine regions and
seven size categories of places of residence. Next,
municipalities with probability proportional to the
demographic structure of individual municipalities were
randomly selected from each strata. In the next step,
PESEL national identification numbers for further study
participants were randomly selected at municipality
level. The age and sex distribution was representative for
each municipality. There were 601 respondents that
turned out to be unavailable after the first selection due
to: refusal—332, absence—182, others—87. For those
individuals replacement persons were selected by quota
sampling (representing the same controlled demographic
characteristics as the primarily selected persons).
The sample then underwent post-stratification weighting
adjustments to level off population distributions in terms of
demographic and geographic parameters.
Questionnaire
The questionnaire was tested for its face and content
validity by four experts in public opinion research, and
adjusted after pilot testing with 140 patients. The final
questionnaire was composed of demographic questions as
well as specific questions concerning experience and
opinions of Poles in the area of GS. The patients’ attitudes
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to various aspects of GS were measured on a five-point
Likert scale (in the analysis, we combined some answers).
The survey was conducted in June 2013 by the means of
face-to-face interviews. The term ‘‘generic substitution’’
was explained to each respondent before the interview has
started. Respondents remained fully anonymous. Ethical
approval was not required for this study.
Statistical methods
SPSS Statistics v.21 (IBM Corp.) software was used for
data analysis. Differences between groups were tested
using the Mann–Whitney U test, while relationships
between variables were examined using rho-Spearmans’s
correlation—these non-parametric tests were used because
Table 1 Study population characteristics in terms of the preferences for GS (trichotomised as having preferences towards generics, towards





Patients who prefer brand
name medicines, n (%)
Patients who have no
preferences, n (%)
Gender
Female 524 293 (56 %) 131 (25 %) 99 (19 %)
Male 477 229 (48 %) 124 (26 %) 128 (27 %)
Age
15–29 year 274 125 (46 %) 81 (30 %) 68 (25 %)
30–39 year 171 84 (49 %) 46 (27 %) 41 (24 %)
40–59 year 333 180 (54 %) 70 (21 %) 83 (25 %)
60 year and over 223 133 (59 %) 29 (13 %) 64 (27 %)
Education
Secondary or lower 850 455 (53 %) 206 (24 %) 189 (22 %)
University 150 69 (46 %) 59 (39 %) 23 (15 %)
Household size
Single 86 48 (56 %) 21 (25 %) 17 (20 %)
2 persons 162 88 (55 %) 42 (26 %) 32 (20 %)
3 persons 208 96 (46 %) 52 (25 %) 60 (29 %)
4 persons 252 134 (53 %) 55 (22 %) 63 (25 %)
5 persons and more 292 156 (54 %) 81 (28 %) 55 (19 %)
Stage of life
Students, single, live with parents 98 37 (38 %) 23 (23 %) 38 (39 %)
Professionally active, single, live with parents 73 35 (48 %) 17 (23 %) 22 (30 %)
Young adults, no kids, own household 23 11 (48 %) 4 (17 %) 8 (35 %)
Family with kids 535 289 (54 %) 112 (21 %) 134 (25 %)
Older families, professionally active, no kids at home 102 51 (50 %) 29 (28 %) 22 (22 %)
Older families, non-working, no kids at home 163 96 (59 %) 46 (28 %) 21 (13 %)
Total household income (net, per month)
Up to PLN 2,999 PLN (USD 999.6) 427 252 (59 %) 92 (22 %) 83 (20 %)
PLN 3,000–4,499 PLN (USD 1,000–1,499.6) 283 142 (50 %) 76 (27 %) 65 (23 %)
PLN 4,500 (USD 1,500) and more 290 129 (45 %) 83 (29 %) 78 (27 %)
Locality
Rural area 386 195 (51 %) 115 (30 %) 76 (20 %)
Urban area 614 322 (53 %) 140 (23 %) 152 (25 %)
Region of Poland
Central 202 106 (53 %) 54 (27 %) 42 (21 %)
North-east 127 70 (56 %) 36 (29 %) 20 (16 %)
North-west 244 118 (48 %) 47 (19 %) 78 (32 %)
South-west 253 141 (55 %) 51 (20 %) 61 (24 %)
South-east 174 87 (50 %) 63 (36 %) 24 (14 %)
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of the non-Gaussian distribution of preferences towards
medicines (tested using the Kolmogorov–Smirnov test).
Results
Preferences of respondents
More than half (52 %) of respondents declared to opt for
generics if faced with a choice between brand name med-
icines and cheaper generic substitutes (23 % of respondents
did not have any specific preferences, 25 % of respondents
were more willing to choose original medicines), as shown
in Table 1.
The level of education statistically differentiated the
choice of respondents: those with a university degree opted
significantly often for a brand name drug (U = 57,553,
p = 0.001).
Net income per household was another factor which
significantly differentiated respondent choices. Individuals
with up to PLN 2,999 net income per household (USD
999.6) significantly more often preferred cheaper generic
substitutes as compared to respondents with PLN
3,000–4,499 (USD 1,000–1,499.6) (U = 60,008;
p = 0,048) and [PLN 4,500 (1,500 USD) (U = 56,684.5;
p = 0,001) net income per household.
Regions of Poland also proved significant in the
context of generic versus brand name drug choices made
by respondents. Generics were found more popular all
across Poland. In south-west Poland, preferences
towards generics were demonstrated to be higher than in
south-east Poland (U = 21,236, p = 0.04). No statisti-
cally significant differences were found between other
regions.
Other analysed factors: sex, age, stage of life, household
size, and locality (rural vs. urban area) did not differentiate
the respondents to a statistically significant extent in terms
(p [ 0.05).
Quality assessment of cheaper generic medicines
Forty-two percent of respondents claimed they had never
used a generic substitute for an original drug. The majority
of those who used cheaper substitutes claimed that generics
represented good or very good quality (81 %). Eighteen
percent who had had previous experience with GS
expressed a negative opinion on generic quality (which
they claimed were bad or very bad) (Table 2).
Taking into account the respondents who had had
experience with generic medicines: the better the respon-
dents assessed the quality of generics, the more willing
they were to choose generics instead of brand name med-
icines (Spearman’s rho = 0.3 and p \ 0.001).
Experiences with generic substitution
The opinion of respondents on the quality of generics they
had used (Table 2) was not shown in comparison with
brand name medicines. Contrariwise, their experience with
GS (Table 3) is explained with reference to their previous
experience with brand name medicines.
Many respondents declared to have had no comparison
between generic and original medicines (44 %). Among
respondents who had had an experience with original
medicines and cheaper equivalents in the past, 72 % did
not observe any difference (both worked well), and 7 %
claimed the generic worked better. 14 and 7 % of
respondents reported experiencing lower efficacy and
aggravation of adverse effects following GS, respectively,
at least once. The analysis that was performed by using the
Chi square test did not show any significant differences in
the experience regarding the effectiveness of generic
medicines (as compared to brand name medicines) in
relation to the socio-demographic variables: gender, age,
stage of life, income of a household, and place of resi-
dence—region and rural versus urban area. (p \ 0.05)
(Table 3).
Opinions of different groups and their effect
on respondents’ attitudes towards generics
The survey also examined which sources of information
about generic medicines are considered by Poles to be
crucial (in a 5-point scale ranging from 1—non-significant,
to 5—significant) (Fig. 1). Respondents’ attitudes towards
generics were found to be: mostly influenced by the
opinions of doctors (4 on a 5-point scale); pharmacists
(3.78 on a 5-point scale); to a lesser extent influenced by
family and friends (3.28 on a 5-point scale); less influenced
by the opinions presented in the mass-media (TV, radio,
press—2.66 on a 5-point scale); and least by the Internet
(2.43 on a 5-point scale).
Table 2 Perception of generics based on respondents’ personal
experience (n = 580)
Experience regarding the cheaper equivalents of original
medicinesa
n %
Patients who have used generic medicines and think that
they are usually of good quality
355 61
Patients who have used generic medicines and think that
they are usually of very good quality.
117 20
Patients who have used generic medicines and think that
they are usually of bad quality
48 8
Patients who have used generic medicines and think that
they are usually of very bad quality
60 10
a Respondents who have never used a cheaper generic substitute for
an original drug were excluded from the analysis
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According to respondents, attitudes towards generics
among doctors, pharmacists, family and friends, and in the
mass-media (TV, radio, press, and the Internet) were rather
positive (an average of 3.6 on a 5-point scale).
Discussion
The results of this study clearly demonstrate that Poles
generally prefer generic medicines over original medicines
and believe that generics are of good quality. The majority of
respondents with prior experience of GS claimed that the
generic substitute and its brand name equivalent proved to be
equally effective. Only 14 % of respondents reported expe-
riencing lower efficacy and 7 % reported an exacerbation of
adverse effects following GS, both on at least one occasion.
Negative experiences associated with the effectiveness of
generic medicines (as compared to brand name medicines)
did not statistically vary with respect to socio-demographic
variables, i.e. gender, age, household income, place of resi-
dence, etc. Other studies also did not find a significant rela-
tionship between negative experiences associated with using

















Patients who did not
notice any difference—a
generic substitute has
always been as effective
as an original drug, n (%)
Patients who claimed






Male 220 33 (15 %) 24 (11 %) 149 (67 %) 14 (7 %)
Female 340 42 (12 %) 21 (6 %) 256 (75 %) 21 (6 %)
Age
15–29 year 118 11 (9 %) 8 (7 %) 92 (78 %) 7 (6 %)
30–39 year 107 19 (18 %) 4 (4 %) 80 (75 %) 4 (4 %)
40–59 year 186 25 (13 %) 19 (10 %) 128 (69 %) 15 (8 %)
60 year and over 149 21 (14 %) 13 (9 %) 105 (70 %) 10 (7 %)
Education
Secondary or lower 478 65 (14 %) 39 (8 %) 341 (71 %) 33 (7 %)
University 82 8 (15 %) 5 (8 %) 66 (71 %) 3 (6 %)
Stage of life
Students, single, live with parents 34 3 (9 %) 1 (3 %) 30 (89 %) 0 (0 %)
Professionally active, single, live
with parents
24 2 (9 %) 3 (13 %) 15 (63 %) 4 (16 %)
Young adults, no kids, own
household
15 1 (3 %) 2 (14 %) 12 (79 %) 1 (5 %)
Family with kids 319 40 (13 %) 25 (8 %) 230 (72 %) 24 (8 %)
Older families, professionally
active, no kids at home
57 7 (13 %) 5 (9 %) 41 (71 %) 4 (7 %)
Older families, non-working, no
kids at home
111 21 (19 %) 6 (6 %) 78 (71 %) 5 (4 %)
Total household income (net, per month)
Up to PLN 2,999 PLN (USD 999.6) 250 39 (15 %) 20 (8 %) 176 (71 %) 15 (6 %)
PLN 3,000–4,499 PLN (USD
1,000–1,499.6)
139 17 (12 %) 3 (2 %) 110 (80 %) 9 (6 %)
PLN 4,500 (USD 1,500) and more 171 17 (10 %) 17 (10 %) 122 (71 %) 15 (8 %)
Locality
Rural area 193 31 (16 %) 19 (10 %) 131 (68 %) 12 (6 %)
Urban area 367 43 (12 %) 24 (7 %) 276 (75 %) 24 (7 %)
Region of Poland
Central 120 14 (12 %) 10 (8 %) 86 (72 %) 10 (8 %)
North-east 64 8 (13 %) 1 (2 %) 50 (78 %) 5 (8 %)
North-west 157 22 (14 %) 24 (15 %) 104 (66 %) 7 (4 %)
South-west 140 20 (14 %) 5 (4 %) 103 (74 %) 12 (9 %)
South-east 79 10 (13 %) 3 (4 %) 64 (81 %) 2 (3 %)
a Respondents who did not have comparison between original and generic medicines were excluded from the analysis
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generic medicines—such as overall dissatisfaction, more
side-effects and lower effectiveness (as compared to brand
name medicines)—and socio-demographic variables e.g.
personal data [9]. Negative experience with generic substi-
tutes, attributed to a lack of efficacy or adverse events, have
also been reported in many earlier studies [9–12]. However,
Himmel et al. [10] concluded that, since adverse effects
caused by generics are inconsistent with pharmacological
findings [13, 14], the experience of lower efficacy or non-
specific side effects of generic medicines may be, at least
among some patients, a nocebo phenomenon [15], (or an
‘‘adverse placebo effect’’).
In the present study, 42 % of respondents claimed that
they had never used a cheaper generic substitute for an
original drug. This can to some extent be explained by
another study by Jaz´win´ska-Tarnawska [16] in which
almost 50 % of Polish patients did not ask for a cheaper
substitute, and pharmacists did not inform patients about
their GS options.
This study also revealed that Poles do take into account
the opinions of doctors and pharmacists, and that these
healthcare professionals typically express positive attitudes
towards generics. There are a number of other studies in
which doctors and pharmacists were shown to have heavily
influenced the choice of patients between brand name or
generic medicines [17–21]. In other studies, many patients
were found to have readily accepted generics if they had
been prescribed or approved by doctors [10, 11, 22, 23] or
recommended by pharmacists [9, 24].
In this study, there was no statistically significant rela-
tionship between the age of respondents and their choice of
generic versus original medicines. There is no consensus in
the literature regarding the differentiation of age on the
preferences of patients between generic and brand name
medicines [21, 24].
There were essentially no statistically significant dif-
ferences between respondents of different genders in terms
of their attitude towards GS. Other studies were in line with
our findings. [9, 23, 25].
Net monthly income per household did statistically
differentiate the respondents’ choices. Respondents with
the highest income per household (over PLN 4,500/USD
1,500) were significantly more likely to opt for brand name
medicines compared to those on the lowest income (PLN
2,999/USD 999.60). In this sense, it can be hypothesized
that drug price is the basic criterion, which determines the
generic versus brand name drug choices made by poorer
patients.
In the study performed by Ha˚konsen et al. [26] in 2012,
which addressed the question of patient perspectives on
GS, patients with higher educational levels were found to
be consistently more likely to hold positive attitudes
towards GS. This conclusion is inconsistent with the results
of our study, which showed that respondents with a uni-
versity education were significantly more likely to prefer
original medicines compared to respondents without
degrees. A study by Professor J Czapin´ski demonstrated
that individuals with university degree earned 42 % more
Fig. 1 Opinions of different groups and their effect on respondents’ attitudes towards generics
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than those with a secondary school education [27]. This
could point to the income level as being the main reason
why university graduates were more likely to prefer brand
name products over generic substitutes. We may infer that
in Poland brand name medicines are only affordable to the
wealthiest and those who are relatively poor prefer gener-
ics. However, this does not provide an in-depth explanation
as to why the attitude of Polish respondents holding a
university degree towards generics is so different compared
with other countries. This question needs to be addressed in
future research. In addition, as our survey focused on
general preferences for generics, further research should be
more detailed and could investigate, for example, the
willingness of patients to switch depending on the type of
generic and therapeutic group.
Conclusion
While most Polish patients appear to have a positive atti-
tude towards generics, a sizable minority prefers original
brand name medicines. This study demonstrated that doc-
tors and pharmacists can influence the perception of
patients towards generic medicines. We thus propose that
the following measures to increase the uptake of generics
in Poland: improved doctor-patient communication; the
promotion of GS at the prescribing stage and enforcing
more effectively the obligation of pharmacists to inform
patients of cheaper medicines.
Acknowledgments We wish to thank all experts from the field of
public opinion research who helped us in verifying the questionnaire.
Funding None.
Conflicts of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Carone G, Schwierz C, Xavier A. Cost-containment policies in
public pharmaceutical spending in the EU. European Economy.
Economic papers [Internet]. 2012 [cited 2014 April 30]; 46:1-64.
http://ec.europa.eu/economy_finance/publications/economic_paper/
2012/pdf/ecp_461_en.pdf.
2. Grzywin´ska D. Rynek leko´w generycznych w Polsce. [Generic
drug market in Poland]. Manager Apteki [Internet]. 2010. [cited
2014May 20]5:2. http://www.nazdrowie.pl/artykul/rynek-lekow-
generycznych-w-polsce. Polish.
3. Ministry of Health of the Republic of Poland. Polityka Lekowa
Pan´stwa 2004–2008 r. [Drug Policy 2004–2008]. [Internet].
Warsaw: 2004 Mar 18 [cited 2014 May 17]. p. 32 http://www2.
mz.gov.pl/wwwfiles/ma_struktura/docs/plekp2004_2008_230304.
pdf. Polish.
4. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the
minimum pricing policy and introduction of brand (generic)
substitution into the pharmaceutical benefits scheme in Australia.
Pharmacoepidemiol Drug Saf. 2001;10(4):295–300.
5. Gossell-Williams M. Generic substitution: a 2005 survey of the
acceptance and perceptions of physicians in Jamaica. West Indian
Med J. 2007;56(5):458–63.
6. Homedes N, Ugalde A. Multisource drug policies in Latin
America: survey of 10 countries. Bull World Health Organ.
2005;83(1):64–70.
7. Simoens S, De Coster S. Sustaining generic medicines markets in
Europe. [Internet]. Leuven: Centre for Pharmaceutical Care and
Pharmaco-economics. 2006. [cited 2014 May 20] http://www.
assogenerici.org/articolihome/simoens-report_2006-04.pdf.
8. Ustawa o refundacji leko´w, s´rodko´w spo _zywczych specjalnego
przeznaczenia _zywieniowego oraz wyrobo´w medycznych 2011
[Reimbursement of Medicines, Foodstuffs Intended for Particular
Nutritional Uses and Medical Devices Act of 2011]. J Laws 2011;
No. 122, item 696, art. 44 ust. 2 (May 12 2011).
9. Kjøenniksen I, Lindbaek M, Grana˚s AG. Patients’ attitudes
towards and experiences of generic drug substitution in Norway.
Pharm World Sci. 2006;28:284–9.
10. Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen
RD, Kochen MM, Gleiter CH, Hummers-Pradier E. What do
primary care patients think about generic drugs? Int J Clin
Pharmacol Ther. 2005;43(10):472–9.
11. Ha˚konsen H, Eilertsen M, Borge H, Borge H, Toverud EL.
Generic substitution: additional challenge for adherence in
hypertensive patients? Curr Med Res Opin. 2009;25:2515–21.
12. Al-Gedadi NA, Hassali MA, Shafie AA. A pilot survey on per-
ceptions and knowledge of generic medicines among consumers
in Penang. Malays Pharm Pract. 2008;6:93–5.
13. Gleiter CH, Gundert-Remy U. Bioinequivalence and drug tox-
icity. How great is the problem and what can be done? Drug Saf.
1994;11:1–6.
14. Meredith PA. Generic drugs. therapeutic equivalence. Drug Saf.
1996;4:233–42.
15. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Non-specific
medication side effects and the nocebo phenomenon. JAMA.
2002;287:622–7.
16. Jaz´win´ska-Tarnawska E. Leki oryginalne i generyczne. Zag-
ro _zenia zwia˛zane ze stosowana˛ farmakoterapia˛ w ro´ _znych grup-
ach pacjento´w oraz planowanie działan´ prewencyjnych. [Original
and generic drugs. Threats associated with drug therapy used in
different groups of patients and planning of prevention inter-
ventions].[Internet]. Wrocław: Wroclaw Medical University.
2012. [cited 2014 May 30]. http://www.farmklin.am.wroc.pl/
wp-content/uploads/2013/Lek_generyczny_2012_materialy.pdf.
Polish.
17. Banahan BF, Kolassa EM. A physician survey on generic drugs
and substitution of critical dose medications. Arch Intern Med.
1997;157(18):2080–8.
18. Ganther JM, Kreling DH. Consumer perceptions of risk and
required cost savings for generic prescription drugs. J Am Pharm
Assoc (Wash). 2000;40(3):378–83.
19. Mott DA, Cline RR. Exploring generic drug use behaviour: the
role of prescribers and pharmacists in the opportunity for generic
drug use and generic substitution. Med Care. 2002;40(8):662–74.
20. Suh DC. Trends of generic substitution in community pharma-
cies. Pharm World Sci. 1999;21(6):260–5.
21. Kobayashi E, Karigome H, Sakurada T, Satoh N, Ueda S.
Patients’ attitudes towards generic drug substitution in Japan.
Health Policy. 2011;99:60–5.
74 Int J Clin Pharm (2015) 37:68–75
123
22. Shrank WH, Cadarette SM, Cox E, Fischer MA, Mehta J,
Brookhart AM, Avorn J, Choudhry NK. Is there a relationship
between patient beliefs or communication about generic drugs
and medication utilization? Med Care. 2009;47:319–25.
23. Valle`s JA, Barreiro M, Cereza G, Ferro JJ, Martı´nez MJ, Escriba`
JM, Iglesias B, Cucurull E, Barcelo´ E. A prospective multicenter
study of the effect of patient education on acceptability of generic
prescribing in general practice. Health Policy. 2003;65:269–75.
24. Heikkila¨ R, Ma¨ntyselka¨ P, Hartikainen-Herranen K, Ahonen R.
Customers’ and physicians’ opinions of and experiences with
generic substitution during the first year in Finland. Health Pol-
icy. 2007;82(3):366–74.
25. Iosifescu A, Halm EA, McGinn T, Siu AL, Federman AD. Beliefs
about generic drugs among elderly adults in hospital-based pri-
mary care practices. Patient Educ Couns. 2008;73(2):377–83.
26. Ha˚konsen H, Toverud EL. A review of patient perspectives on
generics substitution: what are the challenges for optimal drug
use. Generics Biosimilars Init J (GaBI J). 2012;1(1):28–32.
27. Czapin´ski J, Panek T (ed). Diagnoza Społeczna 2011 Warunki i
Jakos´c´ _Zycia Polako´w [Social diagnosis 2011 objective and
subjective quality of life in Poland].[Internet]. Warsaw: The
council for social monitoring. 2011. [cited 2014 Jun 10]. http://ce.
vizja.pl/en/issues/volume/5/issue/3#art214. Polish.
Int J Clin Pharm (2015) 37:68–75 75
123
